Peptide AI Insights
Regulatory-grade answers in seconds.
RWE and HEOR researchers at GLP-1 centric pharma companies are working with the fastest growing market in healthcare yet lack the real-world data necessary to do their job.
Research Bottleneck
Researchers face three core problems
- Payers refuse to reimburse GLP-1s until someone proves they save long-term claim costs by preventing chronic disease.
- GLP-1s curing sleep apnea, liver disease, addiction, and other billion-dollar markets have strong anecdotal evidence, but the FDA doesn't approve label expansion on anecdotes.
- Proving any of this means clinical trials, 68% of pharma's $32B R&D budget, where the wrong population or dosage is costly.
The Product
That's why we build Peptide AI Insights
- Peptide patients' real outcomes, exact dosing and titrations, labs and biomarkers, side effects, and adherence over time.
- All gathered with patient and clinician consent, de-identified, HIPAA-compliant, and built to regulatory-grade standards real-world evidence teams can take straight to payers and the FDA.
- On top of the data, we're building the intelligence layer that turns it into answers in seconds: reports that build the payer dossier, back the label expansion, and pinpoint the exact responder population to de-risk the next trial.
If this interests you...
Access
Join Our Waitlist
Request early access to the data intelligence platform.